Catalent and Moderna expand their manufacturing collaboration

Vaccine maker Moderna and Catalent, a delivery technology provider, have expanded their strategic collaboration to commit a new vial filling line for the manufacture of Moderna’s Covid-19 vaccine, and possibly other investigational clinical programs in the works, at Catalent’s biologics facility in Bloomington, IN.

In June 2020, Catalent and Moderna declared that Catalent would provide aseptic vial filling and packaging from its Bloomington site, along with additional staffing required for around-the-clock manufacturing production of an initial 100 million doses of Moderna’s vaccine, a goal that was accomplished in March.

As part of this expanded agreement, Catalent will now dedicate to Moderna’s use a new high-speed filling line at this site through June 2023. Catalent will also be providing inspection, labeling, cartoning and final packaging for these programs.